SABCS 2022 | The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany, discusses the use of frontline CDK4/6 inhibitors plus endocrine therapy, including with ribociclib and palbociclib, regardless of aromatase inhibition or selective estrogen receptor degraders (SERDs), in endocrine-sensitive metastatic breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.